FLEXION THERAPEUTICS, INC.

Inactive Instrument

Analyst Reco. Flexion Therapeutics, Inc.

Equities

FLXN

US33938J1060

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Northland Securities Downgrades Flexion Therapeutics to Market Perform From Outperform, Price Target $10	19/21/19	MT
FLEXION THERAPEUTICS : HC Wainwright Downgrades Flexion Therapeutics to Neutral From Buy, Price Target at $10	19/21/19	MT
FLEXION THERAPEUTICS : BMO Capital Downgrades Flexion Therapeutics to Market Perform Rating From Outperform, Adjusts Price Target to $12 From $20	12/21/12	MT
FLEXION THERAPEUTICS : Credit Suisse Downgrades Flexion Therapeutics to Neutral from Outperform Following News of Sale to Pacira BioSciences, Lowers PT to $10 from $14	12/21/12	MT
FLEXION THERAPEUTICS : Credit Suisse Downgrades Flexion Therapeutics to Neutral From Outperform, Cuts Price Target to $10 From $14	12/21/12	MT
FLEXION THERAPEUTICS : Raymond James Downgrades Flexion Therapeutics to Market Perform From Strong Buy	12/21/12	MT
FLEXION THERAPEUTICS : Goldman Sachs Adjusts Price Target on Flexion Therapeutics to $6 From $8, Maintains Neutral Rating	06/21/06	MT
FLEXION THERAPEUTICS : Needham Adjusts Flexion Therapeutics' Price Target to $18 From $20, Keeps Buy Rating	05/21/05	MT
FLEXION THERAPEUTICS : Credit Suisse Lowers Flexion Therapeutics' PT to $14 from $17 on Increased Operating Expenses, Keeps Outperform Rating	13/21/13	MT
FLEXION THERAPEUTICS : Raymond James Adjusts Flexion Therapeutics' Price Target to $16 From $18, Keeps Strong Buy Rating	14/21/14	MT
FLEXION THERAPEUTICS : Credit Suisse Lowers Flexion Therapeutics' PT to $17 from $18 After Relatively Flat Q1 Zilretta Sales, Keeps Outperform Rating	14/21/14	MT
FLEXION THERAPEUTICS : Oppenheimer Adjusts Flexion Therapeutics PT to $16 From $19, Maintains Outperform Rating	14/21/14	MT
FLEXION THERAPEUTICS : Raymond James Adjusts Flexion Therapeutics' Price Target to $18 from $19, Keeps Strong Buy Rating	05/20/05	MT
FLEXION THERAPEUTICS : BMO Capital Adjusts Flexion Therapeutics' Price Target to $22 From $23, Keeps at Outperform	05/20/05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer